Wellington Management Company’s Challenging Bristol-Myers Squibb Takeover of Celgene Corporation


Schulte advised Wellington Management Company in challenging the planned $74-billion takeover of global biopharmaceutical company Celgene Corporation by Bristol-Myers Squibb, in which Wellington Management is a shareholder.

Wellington Management holds that, while Bristol-Myers Squibb should develop their business by securing differentiated science to broaden their future revenue base, the Celgene transaction is not the best path toward this goal.

The Schulte team advising Wellington Management is led by Ele Klein (Picture), partner and co-chair of the firm’s global Shareholder Activism Group. The team also includes special counsel Adriana Schwartz and associate David Rothenberg.

Involved fees earner: Eleazer Klein – Schulte Roth & Zabel; David Rothenberg – Schulte Roth & Zabel; Adriana Schwartz – Schulte Roth & Zabel;

Law Firms: Schulte Roth & Zabel;

Clients: Wellington Partners;

Author: Ambrogio Visconti